This study investigated the impact of pazopanib on mRCC patients’ health-related quality of life (HRQOL) in the US community oncology setting. Using real-world retrospective data, this study showed no change over time for HRQOL in mRCC patients after starting on pazopanib, suggesting that pazopanib treatment did not worsen HRQOL.